1026356-52-4

Basic information

• Product Name: ((S)-1-{(S)-1-[(S)-2-Cyclohexyl-1-((2S,4R)-4-methyl-5-oxo-tetrahydro-furan-2-yl)-ethylcarbamoyl]-2-methyl-propylcarbamoyl}-2-naphthalen-1-yl-ethyl)-carbamic acid tert-butyl ester
• CAS NO: 1026356-52-4
• Molecular Weight: 621.817
• Mol File: 1026356-52-4.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: ((S)-1-{(S)-1-[(S)-2-Cyclohexyl-1-((2S,4R)-4-methyl-5-oxo-tetrahydro-furan-2-yl)-ethylcarbamoyl]-2-methyl-propylcarbamoyl}-2-naphthalen-1-yl-ethyl)-carbamic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: ((S)-1-{(S)-1-[(S)-2-Cyclohexyl-1-((2S,4R)-4-methyl-5-oxo-tetrahydro-furan-2-yl)-ethylcarbamoyl]-2-methyl-propylcarbamoyl}-2-naphthalen-1-yl-ethyl)-carbamic acid tert-butyl ester(1026356-52-4)
• EPA Substance Registry System: ((S)-1-{(S)-1-[(S)-2-Cyclohexyl-1-((2S,4R)-4-methyl-5-oxo-tetrahydro-furan-2-yl)-ethylcarbamoyl]-2-methyl-propylcarbamoyl}-2-naphthalen-1-yl-ethyl)-carbamic acid tert-butyl ester(1026356-52-4)

Safety Data

• Hazardous Substances Data: 1026356-52-4(Hazardous Substances Data)

Upstream product

• 146547-04-8 (3R,5S,1'S)-5-<1'-(N-tert-butoxycarbonyl-L-valyl)amino-2'-cyclohexyl>ethyl-3-methyldihydrofuran-2(3H)-one 
• 132094-22-5 (3R,5S,1'S)-5-(1'-tert-butoxycarbonylamino-2'-cyclohexylethyl)-3-methyldihydrofuran-2(3H)-one 
• 55447-00-2 (S)-2-tert-butoxycarbonylamino-3-naphthalen-1-yl-propionic acid 
• 13734-41-3 t-Boc-L-valine 

Relevant articles and documents

Studies of human immunodeficiency virus type 1 (HIV-1) protease inhibitors. III. Structure-activity relationship of HIV-1 protease inhibitors containing cyclohexylalanylalanine hydroxyethylene dipeptide isostere

Systematic replacement of the P4-P2 subsites of substrate-based human immunodeficiency virus type 1 protease (HIV-1 PR) inhibitors containing cyclohexylalanylalanine hydroxyethylene dipeptide isostere (Cha-ψ[H.E.]- Ala) at positions corresponding to the scissile sites of substrates was carried out. The structure-activity relationship revealed that compounds with the combination of hydrophilic P3 and β-branched hydrophobic P2 amino acids generally showed strong inhibitory activity against HIV-1 PR. In particular, compounds 4 (Boc-Orn-Val-Cha-ψ[H.E.]-Ala-NHBu(n); Bu(n) = n- butyl, K(i) = 11 nM) and 6 (Z-Orn-Val-Cha-ψ[H.E.]-Ala-NHBu(n), K(i) = 8 nM) exhibited good enzyme selectivity, possessing no significant inhibitory activities toward closely related aspartic proteases, pepsin, cathepsin D, and renin. As a possible model system for evaluating these compounds, anti- retroviral (anti-Mo-MSV/MLV complex (Mo-MSV = Moloney murine sarcoma virus; MLV = murine leukemia virus)) activity was investigated. Both compounds were found to inhibit moderately the focus formation of Mo-MSV/MLV complex in NIH3T3 cells (compound 4, IC50 = 1.8 μM; compound 6, IC50 = 1.0 μM).